nodes	percent_of_prediction	percent_of_DWPC	metapath
Bosentan—ABCB11—Ethinyl Estradiol—osteoporosis	0.249	0.415	CbGbCtD
Bosentan—CYP2C9—Estropipate—osteoporosis	0.0683	0.114	CbGbCtD
Bosentan—CYP3A4—Estropipate—osteoporosis	0.0397	0.0662	CbGbCtD
Bosentan—CYP3A4—Calcitriol—osteoporosis	0.0397	0.0662	CbGbCtD
Bosentan—CYP2C9—Cholecalciferol—osteoporosis	0.0352	0.0586	CbGbCtD
Bosentan—CYP3A4—Ergocalciferol—osteoporosis	0.0318	0.0529	CbGbCtD
Bosentan—CYP2C9—Estradiol—osteoporosis	0.0284	0.0473	CbGbCtD
Bosentan—CYP3A4—Raloxifene—osteoporosis	0.0265	0.0442	CbGbCtD
Bosentan—CYP3A4—Ethinyl Estradiol—osteoporosis	0.0256	0.0427	CbGbCtD
Bosentan—CYP3A4—Cholecalciferol—osteoporosis	0.0205	0.0341	CbGbCtD
Bosentan—CYP3A4—Conjugated Estrogens—osteoporosis	0.0188	0.0313	CbGbCtD
Bosentan—CYP3A4—Estradiol—osteoporosis	0.0165	0.0275	CbGbCtD
Bosentan—EDNRB—Signaling by GPCR—CALCR—osteoporosis	0.000442	0.00526	CbGpPWpGaD
Bosentan—EDNRB—Signaling by GPCR—PTH1R—osteoporosis	0.000442	0.00526	CbGpPWpGaD
Bosentan—EDNRB—GPCR ligand binding—CNR2—osteoporosis	0.000441	0.00525	CbGpPWpGaD
Bosentan—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP27A1—osteoporosis	0.000415	0.00494	CbGpPWpGaD
Bosentan—EDNRB—GPCR ligand binding—WNT1—osteoporosis	0.000414	0.00494	CbGpPWpGaD
Bosentan—EDNRA—Class A/1 (Rhodopsin-like receptors)—CNR2—osteoporosis	0.000414	0.00493	CbGpPWpGaD
Bosentan—CYP2C9—Oxidation by Cytochrome P450—CYP27A1—osteoporosis	0.000409	0.00487	CbGpPWpGaD
Bosentan—EDNRB—GPCR downstream signaling—MGLL—osteoporosis	0.000387	0.0046	CbGpPWpGaD
Bosentan—EDNRB—GPCR ligand binding—PTHLH—osteoporosis	0.000375	0.00446	CbGpPWpGaD
Bosentan—ABCB11—Metabolism of lipids and lipoproteins—FDPS—osteoporosis	0.000357	0.00426	CbGpPWpGaD
Bosentan—EDNRB—Signaling by GPCR—MGLL—osteoporosis	0.000351	0.00418	CbGpPWpGaD
Bosentan—EDNRA—GPCR downstream signaling—PTH1R—osteoporosis	0.000348	0.00415	CbGpPWpGaD
Bosentan—EDNRA—GPCR downstream signaling—CALCR—osteoporosis	0.000348	0.00415	CbGpPWpGaD
Bosentan—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—osteoporosis	0.000344	0.0041	CbGpPWpGaD
Bosentan—ABCB11—Metabolism of lipids and lipoproteins—GPD2—osteoporosis	0.000339	0.00404	CbGpPWpGaD
Bosentan—EDNRB—Peptide ligand-binding receptors—POMC—osteoporosis	0.000338	0.00403	CbGpPWpGaD
Bosentan—CYP2C9—Phase 1 - Functionalization of compounds—CYP27A1—osteoporosis	0.000336	0.004	CbGpPWpGaD
Bosentan—EDNRB—GPCR ligand binding—CALCA—osteoporosis	0.00033	0.00393	CbGpPWpGaD
Bosentan—EDNRA—GPCR ligand binding—PTH—osteoporosis	0.000324	0.00386	CbGpPWpGaD
Bosentan—EDNRA—Signaling by GPCR—PTH1R—osteoporosis	0.000316	0.00377	CbGpPWpGaD
Bosentan—EDNRA—Signaling by GPCR—CALCR—osteoporosis	0.000316	0.00377	CbGpPWpGaD
Bosentan—EDNRA—GPCR ligand binding—CNR2—osteoporosis	0.000315	0.00376	CbGpPWpGaD
Bosentan—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—osteoporosis	0.0003	0.00357	CbGpPWpGaD
Bosentan—EDNRB—Gastrin-CREB signalling pathway via PKC and MAPK—IL6R—osteoporosis	0.000299	0.00356	CbGpPWpGaD
Bosentan—EDNRA—GPCR ligand binding—WNT1—osteoporosis	0.000297	0.00353	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—SOST—osteoporosis	0.000289	0.00344	CbGpPWpGaD
Bosentan—EDNRA—GPCR downstream signaling—MGLL—osteoporosis	0.000277	0.0033	CbGpPWpGaD
Bosentan—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP27A1—osteoporosis	0.000273	0.00326	CbGpPWpGaD
Bosentan—CYP3A4—Oxidation by Cytochrome P450—CYP27A1—osteoporosis	0.00027	0.00321	CbGpPWpGaD
Bosentan—EDNRA—GPCR ligand binding—PTHLH—osteoporosis	0.000268	0.0032	CbGpPWpGaD
Bosentan—ABCB11—Metabolism of lipids and lipoproteins—OXCT1—osteoporosis	0.000264	0.00314	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—PTH1R—osteoporosis	0.000261	0.00311	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—CALCR—osteoporosis	0.000261	0.00311	CbGpPWpGaD
Bosentan—CYP3A4—Farnesoid X Receptor  Pathway—IRS2—osteoporosis	0.000258	0.00307	CbGpPWpGaD
Bosentan—ABCB11—Metabolism of lipids and lipoproteins—MGLL—osteoporosis	0.000257	0.00306	CbGpPWpGaD
Bosentan—EDNRB—GPCR downstream signaling—PTH—osteoporosis	0.000256	0.00304	CbGpPWpGaD
Bosentan—EDNRA—Signaling by GPCR—MGLL—osteoporosis	0.000251	0.00299	CbGpPWpGaD
Bosentan—EDNRB—GPCR downstream signaling—CNR2—osteoporosis	0.000249	0.00297	CbGpPWpGaD
Bosentan—EDNRA—Peptide ligand-binding receptors—POMC—osteoporosis	0.000242	0.00288	CbGpPWpGaD
Bosentan—EDNRA—GPCR ligand binding—CALCA—osteoporosis	0.000236	0.00281	CbGpPWpGaD
Bosentan—EDNRB—Signaling by GPCR—PTH—osteoporosis	0.000232	0.00276	CbGpPWpGaD
Bosentan—EDNRB—Class A/1 (Rhodopsin-like receptors)—POMC—osteoporosis	0.000227	0.0027	CbGpPWpGaD
Bosentan—EDNRB—Signaling by GPCR—CNR2—osteoporosis	0.000226	0.00269	CbGpPWpGaD
Bosentan—CYP3A4—Phase 1 - Functionalization of compounds—CYP27A1—osteoporosis	0.000222	0.00264	CbGpPWpGaD
Bosentan—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP19A1—osteoporosis	0.000218	0.00259	CbGpPWpGaD
Bosentan—CYP2C9—Oxidation by Cytochrome P450—CYP19A1—osteoporosis	0.000215	0.00256	CbGpPWpGaD
Bosentan—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—IL6R—osteoporosis	0.000214	0.00255	CbGpPWpGaD
Bosentan—EDNRB—Signaling by GPCR—WNT1—osteoporosis	0.000213	0.00253	CbGpPWpGaD
Bosentan—EDNRB—GPCR downstream signaling—PTHLH—osteoporosis	0.000212	0.00252	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—MGLL—osteoporosis	0.000207	0.00247	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—SOST—osteoporosis	0.000207	0.00246	CbGpPWpGaD
Bosentan—ABCB11—Metabolism of lipids and lipoproteins—CYP27A1—osteoporosis	0.000205	0.00245	CbGpPWpGaD
Bosentan—CYP2C9—Arachidonic acid metabolism—GPX1—osteoporosis	0.000205	0.00244	CbGpPWpGaD
Bosentan—Insomnia—Risedronate—osteoporosis	0.000205	0.000648	CcSEcCtD
Bosentan—Anxiety—Zoledronate—osteoporosis	0.000204	0.000646	CcSEcCtD
Bosentan—Loss of consciousness—Conjugated Estrogens—osteoporosis	0.000204	0.000645	CcSEcCtD
Bosentan—Unspecified disorder of skin and subcutaneous tissue—Zoledronate—osteoporosis	0.000203	0.000644	CcSEcCtD
Bosentan—Paraesthesia—Risedronate—osteoporosis	0.000203	0.000643	CcSEcCtD
Bosentan—Pruritus—Estropipate—osteoporosis	0.000203	0.000641	CcSEcCtD
Bosentan—Discomfort—Zoledronate—osteoporosis	0.000202	0.000641	CcSEcCtD
Bosentan—EDNRB—Signaling Pathways—LRP5—osteoporosis	0.000202	0.00241	CbGpPWpGaD
Bosentan—Asthenia—Alendronate—osteoporosis	0.000202	0.00064	CcSEcCtD
Bosentan—Hypersensitivity—Ibandronate—osteoporosis	0.000202	0.00064	CcSEcCtD
Bosentan—Cough—Conjugated Estrogens—osteoporosis	0.000202	0.00064	CcSEcCtD
Bosentan—Dyspnoea—Risedronate—osteoporosis	0.000202	0.000638	CcSEcCtD
Bosentan—Erythema multiforme—Estradiol—osteoporosis	0.000201	0.000638	CcSEcCtD
Bosentan—Hypotension—Pamidronate—osteoporosis	0.000201	0.000636	CcSEcCtD
Bosentan—Dry mouth—Zoledronate—osteoporosis	0.0002	0.000634	CcSEcCtD
Bosentan—Gastrointestinal disorder—Ethinyl Estradiol—osteoporosis	0.0002	0.000634	CcSEcCtD
Bosentan—Fatigue—Ethinyl Estradiol—osteoporosis	0.0002	0.000633	CcSEcCtD
Bosentan—Pruritus—Alendronate—osteoporosis	0.000199	0.000631	CcSEcCtD
Bosentan—Dyspepsia—Risedronate—osteoporosis	0.000199	0.00063	CcSEcCtD
Bosentan—Eye disorder—Estradiol—osteoporosis	0.000199	0.00063	CcSEcCtD
Bosentan—Tinnitus—Estradiol—osteoporosis	0.000199	0.000629	CcSEcCtD
Bosentan—Constipation—Ethinyl Estradiol—osteoporosis	0.000198	0.000628	CcSEcCtD
Bosentan—Hypersensitivity—Calcitriol—osteoporosis	0.000198	0.000627	CcSEcCtD
Bosentan—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—osteoporosis	0.000198	0.00236	CbGpPWpGaD
Bosentan—Flushing—Estradiol—osteoporosis	0.000198	0.000626	CcSEcCtD
Bosentan—Cardiac disorder—Estradiol—osteoporosis	0.000198	0.000626	CcSEcCtD
Bosentan—Arthralgia—Conjugated Estrogens—osteoporosis	0.000197	0.000625	CcSEcCtD
Bosentan—Chest pain—Conjugated Estrogens—osteoporosis	0.000197	0.000625	CcSEcCtD
Bosentan—Asthenia—Ibandronate—osteoporosis	0.000197	0.000623	CcSEcCtD
Bosentan—Anxiety—Conjugated Estrogens—osteoporosis	0.000197	0.000622	CcSEcCtD
Bosentan—Nausea—Etidronic acid—osteoporosis	0.000197	0.000622	CcSEcCtD
Bosentan—Oedema—Zoledronate—osteoporosis	0.000196	0.000622	CcSEcCtD
Bosentan—Anaphylactic shock—Zoledronate—osteoporosis	0.000196	0.000622	CcSEcCtD
Bosentan—Unspecified disorder of skin and subcutaneous tissue—Conjugated Estrogens—osteoporosis	0.000196	0.00062	CcSEcCtD
Bosentan—Musculoskeletal discomfort—Pamidronate—osteoporosis	0.000196	0.00062	CcSEcCtD
Bosentan—Diarrhoea—Estropipate—osteoporosis	0.000196	0.00062	CcSEcCtD
Bosentan—Gastrointestinal disorder—Risedronate—osteoporosis	0.000195	0.000618	CcSEcCtD
Bosentan—Infection—Zoledronate—osteoporosis	0.000195	0.000618	CcSEcCtD
Bosentan—Fatigue—Risedronate—osteoporosis	0.000195	0.000617	CcSEcCtD
Bosentan—Insomnia—Pamidronate—osteoporosis	0.000194	0.000616	CcSEcCtD
Bosentan—Pruritus—Ibandronate—osteoporosis	0.000194	0.000615	CcSEcCtD
Bosentan—EDNRB—Signaling Pathways—LRP6—osteoporosis	0.000194	0.00231	CbGpPWpGaD
Bosentan—Constipation—Risedronate—osteoporosis	0.000193	0.000612	CcSEcCtD
Bosentan—Pain—Risedronate—osteoporosis	0.000193	0.000612	CcSEcCtD
Bosentan—Angiopathy—Estradiol—osteoporosis	0.000193	0.000612	CcSEcCtD
Bosentan—Shock—Zoledronate—osteoporosis	0.000193	0.000612	CcSEcCtD
Bosentan—Paraesthesia—Pamidronate—osteoporosis	0.000193	0.000611	CcSEcCtD
Bosentan—Diarrhoea—Alendronate—osteoporosis	0.000193	0.000611	CcSEcCtD
Bosentan—Asthenia—Calcitriol—osteoporosis	0.000193	0.00061	CcSEcCtD
Bosentan—Nervous system disorder—Zoledronate—osteoporosis	0.000193	0.00061	CcSEcCtD
Bosentan—Immune system disorder—Estradiol—osteoporosis	0.000192	0.000609	CcSEcCtD
Bosentan—EDNRB—Signaling by GPCR—PTHLH—osteoporosis	0.000192	0.00229	CbGpPWpGaD
Bosentan—Thrombocytopenia—Zoledronate—osteoporosis	0.000192	0.000609	CcSEcCtD
Bosentan—Mediastinal disorder—Estradiol—osteoporosis	0.000192	0.000608	CcSEcCtD
Bosentan—Dyspnoea—Pamidronate—osteoporosis	0.000192	0.000607	CcSEcCtD
Bosentan—Tachycardia—Zoledronate—osteoporosis	0.000192	0.000607	CcSEcCtD
Bosentan—Chills—Estradiol—osteoporosis	0.000191	0.000605	CcSEcCtD
Bosentan—Somnolence—Pamidronate—osteoporosis	0.000191	0.000605	CcSEcCtD
Bosentan—Skin disorder—Zoledronate—osteoporosis	0.000191	0.000604	CcSEcCtD
Bosentan—Pruritus—Calcitriol—osteoporosis	0.00019	0.000602	CcSEcCtD
Bosentan—Hyperhidrosis—Zoledronate—osteoporosis	0.00019	0.000601	CcSEcCtD
Bosentan—Gastrointestinal pain—Ethinyl Estradiol—osteoporosis	0.00019	0.000601	CcSEcCtD
Bosentan—Diarrhoea—Raloxifene—osteoporosis	0.00019	0.000601	CcSEcCtD
Bosentan—Dyspepsia—Pamidronate—osteoporosis	0.000189	0.000599	CcSEcCtD
Bosentan—Dizziness—Estropipate—osteoporosis	0.000189	0.000599	CcSEcCtD
Bosentan—Anaphylactic shock—Conjugated Estrogens—osteoporosis	0.000189	0.000599	CcSEcCtD
Bosentan—Oedema—Conjugated Estrogens—osteoporosis	0.000189	0.000599	CcSEcCtD
Bosentan—Infection—Conjugated Estrogens—osteoporosis	0.000188	0.000595	CcSEcCtD
Bosentan—Diarrhoea—Ibandronate—osteoporosis	0.000188	0.000594	CcSEcCtD
Bosentan—Anorexia—Zoledronate—osteoporosis	0.000187	0.000593	CcSEcCtD
Bosentan—Decreased appetite—Pamidronate—osteoporosis	0.000187	0.000592	CcSEcCtD
Bosentan—EDNRA—Signaling Pathways—CALCR—osteoporosis	0.000187	0.00223	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—PTH1R—osteoporosis	0.000187	0.00223	CbGpPWpGaD
Bosentan—Mental disorder—Estradiol—osteoporosis	0.000187	0.000591	CcSEcCtD
Bosentan—EDNRB—GPCR downstream signaling—CALCA—osteoporosis	0.000186	0.00222	CbGpPWpGaD
Bosentan—Dizziness—Alendronate—osteoporosis	0.000186	0.00059	CcSEcCtD
Bosentan—Shock—Conjugated Estrogens—osteoporosis	0.000186	0.000589	CcSEcCtD
Bosentan—Gastrointestinal disorder—Pamidronate—osteoporosis	0.000186	0.000588	CcSEcCtD
Bosentan—Nervous system disorder—Conjugated Estrogens—osteoporosis	0.000185	0.000587	CcSEcCtD
Bosentan—Malnutrition—Estradiol—osteoporosis	0.000185	0.000587	CcSEcCtD
Bosentan—Erythema—Estradiol—osteoporosis	0.000185	0.000587	CcSEcCtD
Bosentan—Fatigue—Pamidronate—osteoporosis	0.000185	0.000587	CcSEcCtD
Bosentan—Gastrointestinal pain—Risedronate—osteoporosis	0.000185	0.000586	CcSEcCtD
Bosentan—Tachycardia—Conjugated Estrogens—osteoporosis	0.000185	0.000584	CcSEcCtD
Bosentan—Urticaria—Ethinyl Estradiol—osteoporosis	0.000184	0.000583	CcSEcCtD
Bosentan—Constipation—Pamidronate—osteoporosis	0.000184	0.000582	CcSEcCtD
Bosentan—Pain—Pamidronate—osteoporosis	0.000184	0.000582	CcSEcCtD
Bosentan—Diarrhoea—Calcitriol—osteoporosis	0.000184	0.000582	CcSEcCtD
Bosentan—Skin disorder—Conjugated Estrogens—osteoporosis	0.000184	0.000582	CcSEcCtD
Bosentan—Hypotension—Zoledronate—osteoporosis	0.000184	0.000581	CcSEcCtD
Bosentan—Abdominal pain—Ethinyl Estradiol—osteoporosis	0.000183	0.000581	CcSEcCtD
Bosentan—Body temperature increased—Ethinyl Estradiol—osteoporosis	0.000183	0.000581	CcSEcCtD
Bosentan—Dizziness—Raloxifene—osteoporosis	0.000183	0.00058	CcSEcCtD
Bosentan—EDNRA—GPCR downstream signaling—PTH—osteoporosis	0.000183	0.00218	CbGpPWpGaD
Bosentan—Hyperhidrosis—Conjugated Estrogens—osteoporosis	0.000183	0.000579	CcSEcCtD
Bosentan—Flatulence—Estradiol—osteoporosis	0.000183	0.000579	CcSEcCtD
Bosentan—Vomiting—Estropipate—osteoporosis	0.000182	0.000576	CcSEcCtD
Bosentan—Dizziness—Ibandronate—osteoporosis	0.000182	0.000575	CcSEcCtD
Bosentan—Rash—Estropipate—osteoporosis	0.00018	0.000571	CcSEcCtD
Bosentan—Dermatitis—Estropipate—osteoporosis	0.00018	0.000571	CcSEcCtD
Bosentan—Anorexia—Conjugated Estrogens—osteoporosis	0.00018	0.000571	CcSEcCtD
Bosentan—Urticaria—Risedronate—osteoporosis	0.00018	0.000569	CcSEcCtD
Bosentan—Back pain—Estradiol—osteoporosis	0.000179	0.000568	CcSEcCtD
Bosentan—Headache—Estropipate—osteoporosis	0.000179	0.000568	CcSEcCtD
Bosentan—Vomiting—Alendronate—osteoporosis	0.000179	0.000567	CcSEcCtD
Bosentan—Musculoskeletal discomfort—Zoledronate—osteoporosis	0.000179	0.000566	CcSEcCtD
Bosentan—Body temperature increased—Risedronate—osteoporosis	0.000179	0.000566	CcSEcCtD
Bosentan—Abdominal pain—Risedronate—osteoporosis	0.000179	0.000566	CcSEcCtD
Bosentan—CYP2C9—Biological oxidations—CYP27A1—osteoporosis	0.000179	0.00213	CbGpPWpGaD
Bosentan—Muscle spasms—Estradiol—osteoporosis	0.000178	0.000564	CcSEcCtD
Bosentan—EDNRA—GPCR downstream signaling—CNR2—osteoporosis	0.000178	0.00212	CbGpPWpGaD
Bosentan—Rash—Alendronate—osteoporosis	0.000178	0.000563	CcSEcCtD
Bosentan—Insomnia—Zoledronate—osteoporosis	0.000178	0.000562	CcSEcCtD
Bosentan—CYP3A4—Tryptophan metabolism—CYP19A1—osteoporosis	0.000178	0.00212	CbGpPWpGaD
Bosentan—Dermatitis—Alendronate—osteoporosis	0.000178	0.000562	CcSEcCtD
Bosentan—Hypotension—Conjugated Estrogens—osteoporosis	0.000177	0.000559	CcSEcCtD
Bosentan—Headache—Alendronate—osteoporosis	0.000177	0.000559	CcSEcCtD
Bosentan—CYP2C9—Phase 1 - Functionalization of compounds—CYP19A1—osteoporosis	0.000177	0.0021	CbGpPWpGaD
Bosentan—Paraesthesia—Zoledronate—osteoporosis	0.000176	0.000558	CcSEcCtD
Bosentan—Vomiting—Raloxifene—osteoporosis	0.000176	0.000558	CcSEcCtD
Bosentan—CYP2C9—Metapathway biotransformation—CYP27A1—osteoporosis	0.000176	0.0021	CbGpPWpGaD
Bosentan—Gastrointestinal pain—Pamidronate—osteoporosis	0.000176	0.000557	CcSEcCtD
Bosentan—Dyspnoea—Zoledronate—osteoporosis	0.000175	0.000554	CcSEcCtD
Bosentan—Rash—Raloxifene—osteoporosis	0.000175	0.000553	CcSEcCtD
Bosentan—Dermatitis—Raloxifene—osteoporosis	0.000175	0.000553	CcSEcCtD
Bosentan—Somnolence—Zoledronate—osteoporosis	0.000175	0.000553	CcSEcCtD
Bosentan—ABCB11—Metabolism of lipids and lipoproteins—P4HB—osteoporosis	0.000175	0.00208	CbGpPWpGaD
Bosentan—Vomiting—Ibandronate—osteoporosis	0.000175	0.000552	CcSEcCtD
Bosentan—Tremor—Estradiol—osteoporosis	0.000174	0.00055	CcSEcCtD
Bosentan—Headache—Raloxifene—osteoporosis	0.000174	0.00055	CcSEcCtD
Bosentan—Rash—Ibandronate—osteoporosis	0.000173	0.000548	CcSEcCtD
Bosentan—Dermatitis—Ibandronate—osteoporosis	0.000173	0.000547	CcSEcCtD
Bosentan—Dyspepsia—Zoledronate—osteoporosis	0.000173	0.000547	CcSEcCtD
Bosentan—EDNRB—GPCR ligand binding—POMC—osteoporosis	0.000173	0.00206	CbGpPWpGaD
Bosentan—Musculoskeletal discomfort—Conjugated Estrogens—osteoporosis	0.000172	0.000545	CcSEcCtD
Bosentan—Headache—Ibandronate—osteoporosis	0.000172	0.000544	CcSEcCtD
Bosentan—Insomnia—Conjugated Estrogens—osteoporosis	0.000171	0.000542	CcSEcCtD
Bosentan—Hypersensitivity—Ethinyl Estradiol—osteoporosis	0.000171	0.000541	CcSEcCtD
Bosentan—Vomiting—Calcitriol—osteoporosis	0.000171	0.000541	CcSEcCtD
Bosentan—Decreased appetite—Zoledronate—osteoporosis	0.000171	0.000541	CcSEcCtD
Bosentan—Nausea—Estropipate—osteoporosis	0.00017	0.000538	CcSEcCtD
Bosentan—Body temperature increased—Pamidronate—osteoporosis	0.00017	0.000538	CcSEcCtD
Bosentan—Abdominal pain—Pamidronate—osteoporosis	0.00017	0.000538	CcSEcCtD
Bosentan—Paraesthesia—Conjugated Estrogens—osteoporosis	0.00017	0.000538	CcSEcCtD
Bosentan—Gastrointestinal disorder—Zoledronate—osteoporosis	0.00017	0.000537	CcSEcCtD
Bosentan—Angioedema—Estradiol—osteoporosis	0.000169	0.000536	CcSEcCtD
Bosentan—Rash—Calcitriol—osteoporosis	0.000169	0.000536	CcSEcCtD
Bosentan—EDNRB—Signaling by GPCR—CALCA—osteoporosis	0.000169	0.00202	CbGpPWpGaD
Bosentan—Fatigue—Zoledronate—osteoporosis	0.000169	0.000536	CcSEcCtD
Bosentan—Dermatitis—Calcitriol—osteoporosis	0.000169	0.000536	CcSEcCtD
Bosentan—Dyspnoea—Conjugated Estrogens—osteoporosis	0.000169	0.000534	CcSEcCtD
Bosentan—Headache—Calcitriol—osteoporosis	0.000168	0.000533	CcSEcCtD
Bosentan—Somnolence—Conjugated Estrogens—osteoporosis	0.000168	0.000532	CcSEcCtD
Bosentan—Pain—Zoledronate—osteoporosis	0.000168	0.000532	CcSEcCtD
Bosentan—Constipation—Zoledronate—osteoporosis	0.000168	0.000532	CcSEcCtD
Bosentan—Nausea—Alendronate—osteoporosis	0.000167	0.00053	CcSEcCtD
Bosentan—Hypersensitivity—Risedronate—osteoporosis	0.000167	0.000528	CcSEcCtD
Bosentan—Vertigo—Estradiol—osteoporosis	0.000167	0.000527	CcSEcCtD
Bosentan—Dyspepsia—Conjugated Estrogens—osteoporosis	0.000166	0.000527	CcSEcCtD
Bosentan—Asthenia—Ethinyl Estradiol—osteoporosis	0.000166	0.000527	CcSEcCtD
Bosentan—Syncope—Estradiol—osteoporosis	0.000166	0.000527	CcSEcCtD
Bosentan—EDNRA—Signaling by GPCR—PTH—osteoporosis	0.000166	0.00198	CbGpPWpGaD
Bosentan—Nausea—Raloxifene—osteoporosis	0.000165	0.000521	CcSEcCtD
Bosentan—Decreased appetite—Conjugated Estrogens—osteoporosis	0.000164	0.00052	CcSEcCtD
Bosentan—Pruritus—Ethinyl Estradiol—osteoporosis	0.000164	0.00052	CcSEcCtD
Bosentan—Palpitations—Estradiol—osteoporosis	0.000164	0.000519	CcSEcCtD
Bosentan—EDNRB—Signaling Pathways—TLN1—osteoporosis	0.000163	0.00195	CbGpPWpGaD
Bosentan—Gastrointestinal disorder—Conjugated Estrogens—osteoporosis	0.000163	0.000517	CcSEcCtD
Bosentan—Fatigue—Conjugated Estrogens—osteoporosis	0.000163	0.000516	CcSEcCtD
Bosentan—Nausea—Ibandronate—osteoporosis	0.000163	0.000516	CcSEcCtD
Bosentan—Loss of consciousness—Estradiol—osteoporosis	0.000163	0.000516	CcSEcCtD
Bosentan—Asthenia—Risedronate—osteoporosis	0.000162	0.000514	CcSEcCtD
Bosentan—EDNRA—Class A/1 (Rhodopsin-like receptors)—POMC—osteoporosis	0.000162	0.00193	CbGpPWpGaD
Bosentan—EDNRA—Signaling by GPCR—CNR2—osteoporosis	0.000162	0.00193	CbGpPWpGaD
Bosentan—Cough—Estradiol—osteoporosis	0.000162	0.000512	CcSEcCtD
Bosentan—Pain—Conjugated Estrogens—osteoporosis	0.000162	0.000512	CcSEcCtD
Bosentan—Constipation—Conjugated Estrogens—osteoporosis	0.000162	0.000512	CcSEcCtD
Bosentan—Gastrointestinal pain—Zoledronate—osteoporosis	0.000161	0.000508	CcSEcCtD
Bosentan—Pruritus—Risedronate—osteoporosis	0.00016	0.000507	CcSEcCtD
Bosentan—Nausea—Calcitriol—osteoporosis	0.00016	0.000505	CcSEcCtD
Bosentan—ABCB11—Metabolism—PKM—osteoporosis	0.000159	0.0019	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—FDPS—osteoporosis	0.000159	0.0019	CbGpPWpGaD
Bosentan—Diarrhoea—Ethinyl Estradiol—osteoporosis	0.000159	0.000503	CcSEcCtD
Bosentan—Hypersensitivity—Pamidronate—osteoporosis	0.000158	0.000502	CcSEcCtD
Bosentan—Chest pain—Estradiol—osteoporosis	0.000158	0.0005	CcSEcCtD
Bosentan—Arthralgia—Estradiol—osteoporosis	0.000158	0.0005	CcSEcCtD
Bosentan—Anxiety—Estradiol—osteoporosis	0.000157	0.000498	CcSEcCtD
Bosentan—Unspecified disorder of skin and subcutaneous tissue—Estradiol—osteoporosis	0.000157	0.000496	CcSEcCtD
Bosentan—Urticaria—Zoledronate—osteoporosis	0.000156	0.000494	CcSEcCtD
Bosentan—Discomfort—Estradiol—osteoporosis	0.000156	0.000494	CcSEcCtD
Bosentan—Abdominal pain—Zoledronate—osteoporosis	0.000155	0.000492	CcSEcCtD
Bosentan—Body temperature increased—Zoledronate—osteoporosis	0.000155	0.000492	CcSEcCtD
Bosentan—Diarrhoea—Risedronate—osteoporosis	0.000155	0.00049	CcSEcCtD
Bosentan—Gastrointestinal pain—Conjugated Estrogens—osteoporosis	0.000155	0.00049	CcSEcCtD
Bosentan—Dry mouth—Estradiol—osteoporosis	0.000154	0.000489	CcSEcCtD
Bosentan—Asthenia—Pamidronate—osteoporosis	0.000154	0.000488	CcSEcCtD
Bosentan—Dizziness—Ethinyl Estradiol—osteoporosis	0.000153	0.000486	CcSEcCtD
Bosentan—EDNRA—Signaling by GPCR—WNT1—osteoporosis	0.000152	0.00181	CbGpPWpGaD
Bosentan—Pruritus—Pamidronate—osteoporosis	0.000152	0.000482	CcSEcCtD
Bosentan—EDNRA—GPCR downstream signaling—PTHLH—osteoporosis	0.000152	0.00181	CbGpPWpGaD
Bosentan—Oedema—Estradiol—osteoporosis	0.000151	0.000479	CcSEcCtD
Bosentan—Anaphylactic shock—Estradiol—osteoporosis	0.000151	0.000479	CcSEcCtD
Bosentan—ABCB11—Metabolism—GPD2—osteoporosis	0.000151	0.0018	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—PGLS—osteoporosis	0.000151	0.0018	CbGpPWpGaD
Bosentan—Infection—Estradiol—osteoporosis	0.00015	0.000476	CcSEcCtD
Bosentan—Urticaria—Conjugated Estrogens—osteoporosis	0.00015	0.000476	CcSEcCtD
Bosentan—Dizziness—Risedronate—osteoporosis	0.00015	0.000474	CcSEcCtD
Bosentan—Body temperature increased—Conjugated Estrogens—osteoporosis	0.00015	0.000473	CcSEcCtD
Bosentan—Abdominal pain—Conjugated Estrogens—osteoporosis	0.00015	0.000473	CcSEcCtD
Bosentan—Shock—Estradiol—osteoporosis	0.000149	0.000471	CcSEcCtD
Bosentan—Nervous system disorder—Estradiol—osteoporosis	0.000148	0.00047	CcSEcCtD
Bosentan—EDNRA—Signaling Pathways—MGLL—osteoporosis	0.000148	0.00177	CbGpPWpGaD
Bosentan—Tachycardia—Estradiol—osteoporosis	0.000148	0.000468	CcSEcCtD
Bosentan—Vomiting—Ethinyl Estradiol—osteoporosis	0.000148	0.000467	CcSEcCtD
Bosentan—Diarrhoea—Pamidronate—osteoporosis	0.000147	0.000466	CcSEcCtD
Bosentan—Skin disorder—Estradiol—osteoporosis	0.000147	0.000465	CcSEcCtD
Bosentan—Hyperhidrosis—Estradiol—osteoporosis	0.000146	0.000463	CcSEcCtD
Bosentan—Rash—Ethinyl Estradiol—osteoporosis	0.000146	0.000463	CcSEcCtD
Bosentan—Dermatitis—Ethinyl Estradiol—osteoporosis	0.000146	0.000463	CcSEcCtD
Bosentan—Headache—Ethinyl Estradiol—osteoporosis	0.000145	0.00046	CcSEcCtD
Bosentan—EDNRA—Signaling Pathways—LRP5—osteoporosis	0.000145	0.00173	CbGpPWpGaD
Bosentan—Hypersensitivity—Zoledronate—osteoporosis	0.000145	0.000458	CcSEcCtD
Bosentan—Vomiting—Risedronate—osteoporosis	0.000144	0.000455	CcSEcCtD
Bosentan—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP19A1—osteoporosis	0.000144	0.00171	CbGpPWpGaD
Bosentan—Rash—Risedronate—osteoporosis	0.000143	0.000451	CcSEcCtD
Bosentan—Dermatitis—Risedronate—osteoporosis	0.000142	0.000451	CcSEcCtD
Bosentan—Dizziness—Pamidronate—osteoporosis	0.000142	0.00045	CcSEcCtD
Bosentan—CYP3A4—Oxidation by Cytochrome P450—CYP19A1—osteoporosis	0.000142	0.00169	CbGpPWpGaD
Bosentan—Headache—Risedronate—osteoporosis	0.000142	0.000449	CcSEcCtD
Bosentan—EDNRB—Signaling Pathways—P4HB—osteoporosis	0.000141	0.00168	CbGpPWpGaD
Bosentan—Asthenia—Zoledronate—osteoporosis	0.000141	0.000446	CcSEcCtD
Bosentan—Hypersensitivity—Conjugated Estrogens—osteoporosis	0.000139	0.000441	CcSEcCtD
Bosentan—Pruritus—Zoledronate—osteoporosis	0.000139	0.00044	CcSEcCtD
Bosentan—EDNRA—Signaling Pathways—LRP6—osteoporosis	0.000139	0.00165	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—ATIC—osteoporosis	0.000138	0.00164	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—PNP—osteoporosis	0.000138	0.00164	CbGpPWpGaD
Bosentan—Musculoskeletal discomfort—Estradiol—osteoporosis	0.000138	0.000437	CcSEcCtD
Bosentan—Nausea—Ethinyl Estradiol—osteoporosis	0.000138	0.000436	CcSEcCtD
Bosentan—EDNRA—Signaling by GPCR—PTHLH—osteoporosis	0.000138	0.00164	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—PTH—osteoporosis	0.000137	0.00163	CbGpPWpGaD
Bosentan—Insomnia—Estradiol—osteoporosis	0.000137	0.000433	CcSEcCtD
Bosentan—Vomiting—Pamidronate—osteoporosis	0.000137	0.000433	CcSEcCtD
Bosentan—Paraesthesia—Estradiol—osteoporosis	0.000136	0.00043	CcSEcCtD
Bosentan—Asthenia—Conjugated Estrogens—osteoporosis	0.000136	0.00043	CcSEcCtD
Bosentan—Rash—Pamidronate—osteoporosis	0.000136	0.000429	CcSEcCtD
Bosentan—Dermatitis—Pamidronate—osteoporosis	0.000135	0.000429	CcSEcCtD
Bosentan—Dyspnoea—Estradiol—osteoporosis	0.000135	0.000427	CcSEcCtD
Bosentan—EDNRB—Signaling Pathways—RAP1A—osteoporosis	0.000135	0.00161	CbGpPWpGaD
Bosentan—Headache—Pamidronate—osteoporosis	0.000135	0.000426	CcSEcCtD
Bosentan—Somnolence—Estradiol—osteoporosis	0.000135	0.000426	CcSEcCtD
Bosentan—Diarrhoea—Zoledronate—osteoporosis	0.000134	0.000425	CcSEcCtD
Bosentan—Nausea—Risedronate—osteoporosis	0.000134	0.000425	CcSEcCtD
Bosentan—Pruritus—Conjugated Estrogens—osteoporosis	0.000134	0.000424	CcSEcCtD
Bosentan—EDNRB—Signaling Pathways—CNR2—osteoporosis	0.000134	0.00159	CbGpPWpGaD
Bosentan—EDNRA—GPCR downstream signaling—CALCA—osteoporosis	0.000133	0.00159	CbGpPWpGaD
Bosentan—Dyspepsia—Estradiol—osteoporosis	0.000133	0.000422	CcSEcCtD
Bosentan—EDNRB—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—osteoporosis	0.000133	0.00158	CbGpPWpGaD
Bosentan—EDNRB—GPCR downstream signaling—ADCY5—osteoporosis	0.000133	0.00158	CbGpPWpGaD
Bosentan—Decreased appetite—Estradiol—osteoporosis	0.000132	0.000417	CcSEcCtD
Bosentan—EDNRB—Signaling Pathways—NFATC1—osteoporosis	0.000131	0.00157	CbGpPWpGaD
Bosentan—CYP2C9—Cytochrome P450 - arranged by substrate type—POMC—osteoporosis	0.000131	0.00156	CbGpPWpGaD
Bosentan—Gastrointestinal disorder—Estradiol—osteoporosis	0.000131	0.000414	CcSEcCtD
Bosentan—Fatigue—Estradiol—osteoporosis	0.00013	0.000413	CcSEcCtD
Bosentan—EDNRB—Signaling Pathways—DKK1—osteoporosis	0.00013	0.00155	CbGpPWpGaD
Bosentan—Dizziness—Zoledronate—osteoporosis	0.00013	0.000411	CcSEcCtD
Bosentan—Constipation—Estradiol—osteoporosis	0.000129	0.00041	CcSEcCtD
Bosentan—Pain—Estradiol—osteoporosis	0.000129	0.00041	CcSEcCtD
Bosentan—Diarrhoea—Conjugated Estrogens—osteoporosis	0.000129	0.00041	CcSEcCtD
Bosentan—Nausea—Pamidronate—osteoporosis	0.000128	0.000404	CcSEcCtD
Bosentan—EDNRB—Signaling Pathways—WNT1—osteoporosis	0.000126	0.0015	CbGpPWpGaD
Bosentan—Dizziness—Conjugated Estrogens—osteoporosis	0.000125	0.000396	CcSEcCtD
Bosentan—Vomiting—Zoledronate—osteoporosis	0.000125	0.000395	CcSEcCtD
Bosentan—Rash—Zoledronate—osteoporosis	0.000124	0.000392	CcSEcCtD
Bosentan—Gastrointestinal pain—Estradiol—osteoporosis	0.000124	0.000392	CcSEcCtD
Bosentan—Dermatitis—Zoledronate—osteoporosis	0.000124	0.000392	CcSEcCtD
Bosentan—EDNRA—GPCR ligand binding—POMC—osteoporosis	0.000124	0.00147	CbGpPWpGaD
Bosentan—Headache—Zoledronate—osteoporosis	0.000123	0.00039	CcSEcCtD
Bosentan—EDNRB—Signaling Pathways—FGA—osteoporosis	0.000122	0.00146	CbGpPWpGaD
Bosentan—EDNRA—Signaling by GPCR—CALCA—osteoporosis	0.000121	0.00144	CbGpPWpGaD
Bosentan—EDNRB—Signaling by GPCR—ADCY5—osteoporosis	0.00012	0.00143	CbGpPWpGaD
Bosentan—Vomiting—Conjugated Estrogens—osteoporosis	0.00012	0.000381	CcSEcCtD
Bosentan—Urticaria—Estradiol—osteoporosis	0.00012	0.000381	CcSEcCtD
Bosentan—Abdominal pain—Estradiol—osteoporosis	0.00012	0.000379	CcSEcCtD
Bosentan—Body temperature increased—Estradiol—osteoporosis	0.00012	0.000379	CcSEcCtD
Bosentan—CYP2C9—Metabolism of lipids and lipoproteins—FDPS—osteoporosis	0.000119	0.00142	CbGpPWpGaD
Bosentan—Rash—Conjugated Estrogens—osteoporosis	0.000119	0.000377	CcSEcCtD
Bosentan—Dermatitis—Conjugated Estrogens—osteoporosis	0.000119	0.000377	CcSEcCtD
Bosentan—Headache—Conjugated Estrogens—osteoporosis	0.000118	0.000375	CcSEcCtD
Bosentan—CYP3A4—Biological oxidations—CYP27A1—osteoporosis	0.000118	0.0014	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—CA2—osteoporosis	0.000117	0.0014	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—OXCT1—osteoporosis	0.000117	0.0014	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—TLN1—osteoporosis	0.000117	0.00139	CbGpPWpGaD
Bosentan—Nausea—Zoledronate—osteoporosis	0.000117	0.000369	CcSEcCtD
Bosentan—CYP3A4—Phase 1 - Functionalization of compounds—CYP19A1—osteoporosis	0.000116	0.00139	CbGpPWpGaD
Bosentan—CYP3A4—Metapathway biotransformation—CYP27A1—osteoporosis	0.000116	0.00138	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—MGLL—osteoporosis	0.000114	0.00136	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—PTHLH—osteoporosis	0.000114	0.00135	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—BMP2—osteoporosis	0.000114	0.00135	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism of lipids and lipoproteins—GPD2—osteoporosis	0.000113	0.00135	CbGpPWpGaD
Bosentan—Nausea—Conjugated Estrogens—osteoporosis	0.000112	0.000356	CcSEcCtD
Bosentan—Hypersensitivity—Estradiol—osteoporosis	0.000112	0.000353	CcSEcCtD
Bosentan—EDNRB—Signaling Pathways—FGB—osteoporosis	0.000111	0.00132	CbGpPWpGaD
Bosentan—Asthenia—Estradiol—osteoporosis	0.000109	0.000344	CcSEcCtD
Bosentan—ABCB11—Metabolism of lipids and lipoproteins—CYP19A1—osteoporosis	0.000108	0.00128	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—PSMA2—osteoporosis	0.000107	0.00128	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—PSMA5—osteoporosis	0.000107	0.00128	CbGpPWpGaD
Bosentan—Pruritus—Estradiol—osteoporosis	0.000107	0.000339	CcSEcCtD
Bosentan—CYP2C9—Phase 1 - Functionalization of compounds—POMC—osteoporosis	0.000106	0.00126	CbGpPWpGaD
Bosentan—Diarrhoea—Estradiol—osteoporosis	0.000104	0.000328	CcSEcCtD
Bosentan—EDNRA—Signaling Pathways—P4HB—osteoporosis	0.000101	0.0012	CbGpPWpGaD
Bosentan—Dizziness—Estradiol—osteoporosis	0.0001	0.000317	CcSEcCtD
Bosentan—EDNRB—Signaling Pathways—CALCA—osteoporosis	0.0001	0.00119	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—PTH—osteoporosis	9.81e-05	0.00117	CbGpPWpGaD
Bosentan—EDNRB—GPCR downstream signaling—POMC—osteoporosis	9.76e-05	0.00116	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—IDH2—osteoporosis	9.73e-05	0.00116	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—RAP1A—osteoporosis	9.65e-05	0.00115	CbGpPWpGaD
Bosentan—Vomiting—Estradiol—osteoporosis	9.62e-05	0.000305	CcSEcCtD
Bosentan—EDNRA—Signaling Pathways—CNR2—osteoporosis	9.56e-05	0.00114	CbGpPWpGaD
Bosentan—Rash—Estradiol—osteoporosis	9.54e-05	0.000302	CcSEcCtD
Bosentan—Dermatitis—Estradiol—osteoporosis	9.53e-05	0.000302	CcSEcCtD
Bosentan—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—osteoporosis	9.52e-05	0.00113	CbGpPWpGaD
Bosentan—EDNRA—GPCR downstream signaling—ADCY5—osteoporosis	9.49e-05	0.00113	CbGpPWpGaD
Bosentan—Headache—Estradiol—osteoporosis	9.48e-05	0.0003	CcSEcCtD
Bosentan—EDNRA—Signaling Pathways—NFATC1—osteoporosis	9.41e-05	0.00112	CbGpPWpGaD
Bosentan—CYP2C9—Biological oxidations—CYP19A1—osteoporosis	9.38e-05	0.00112	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—DKK1—osteoporosis	9.34e-05	0.00111	CbGpPWpGaD
Bosentan—CYP2C9—Metapathway biotransformation—CYP19A1—osteoporosis	9.25e-05	0.0011	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—CYP27A1—osteoporosis	9.14e-05	0.00109	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—KL—osteoporosis	9.08e-05	0.00108	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—WNT1—osteoporosis	8.99e-05	0.00107	CbGpPWpGaD
Bosentan—Nausea—Estradiol—osteoporosis	8.99e-05	0.000285	CcSEcCtD
Bosentan—ABCB11—Metabolism—ACP5—osteoporosis	8.9e-05	0.00106	CbGpPWpGaD
Bosentan—EDNRB—Signaling by GPCR—POMC—osteoporosis	8.86e-05	0.00106	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism of lipids and lipoproteins—OXCT1—osteoporosis	8.8e-05	0.00105	CbGpPWpGaD
Bosentan—ABCB11—Metabolism of lipids and lipoproteins—GPX1—osteoporosis	8.78e-05	0.00105	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—FGA—osteoporosis	8.75e-05	0.00104	CbGpPWpGaD
Bosentan—EDNRB—Signaling by GPCR—IL6R—osteoporosis	8.64e-05	0.00103	CbGpPWpGaD
Bosentan—CYP3A4—Cytochrome P450 - arranged by substrate type—POMC—osteoporosis	8.63e-05	0.00103	CbGpPWpGaD
Bosentan—EDNRA—Signaling by GPCR—ADCY5—osteoporosis	8.62e-05	0.00103	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism of lipids and lipoproteins—MGLL—osteoporosis	8.57e-05	0.00102	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—TPI1—osteoporosis	8.27e-05	0.000985	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—PTHLH—osteoporosis	8.13e-05	0.000969	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—BMP2—osteoporosis	8.13e-05	0.000969	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—FGB—osteoporosis	7.96e-05	0.000948	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—P4HB—osteoporosis	7.78e-05	0.000926	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—PSMA2—osteoporosis	7.68e-05	0.000915	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—PSMA5—osteoporosis	7.68e-05	0.000915	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—GAPDH—osteoporosis	7.63e-05	0.000909	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—RAP1A—osteoporosis	7.43e-05	0.000885	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—CALCA—osteoporosis	7.16e-05	0.000853	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—ADCY5—osteoporosis	7.12e-05	0.000848	CbGpPWpGaD
Bosentan—CYP3A4—Phase 1 - Functionalization of compounds—POMC—osteoporosis	7e-05	0.000833	CbGpPWpGaD
Bosentan—EDNRA—GPCR downstream signaling—POMC—osteoporosis	6.98e-05	0.000832	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—SPP1—osteoporosis	6.88e-05	0.00082	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism of lipids and lipoproteins—CYP27A1—osteoporosis	6.86e-05	0.000817	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—KL—osteoporosis	6.5e-05	0.000774	CbGpPWpGaD
Bosentan—ABCB11—Metabolism of lipids and lipoproteins—POMC—osteoporosis	6.48e-05	0.000772	CbGpPWpGaD
Bosentan—EDNRA—Signaling by GPCR—POMC—osteoporosis	6.34e-05	0.000755	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—IRS2—osteoporosis	6.23e-05	0.000742	CbGpPWpGaD
Bosentan—EDNRA—Signaling by GPCR—IL6R—osteoporosis	6.19e-05	0.000737	CbGpPWpGaD
Bosentan—CYP3A4—Biological oxidations—CYP19A1—osteoporosis	6.18e-05	0.000737	CbGpPWpGaD
Bosentan—CYP3A4—Metapathway biotransformation—CYP19A1—osteoporosis	6.1e-05	0.000727	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—LEP—osteoporosis	6.09e-05	0.000726	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—ENO1—osteoporosis	6.01e-05	0.000716	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—PSMA5—osteoporosis	5.92e-05	0.000705	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—PSMA2—osteoporosis	5.92e-05	0.000705	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism of lipids and lipoproteins—P4HB—osteoporosis	5.83e-05	0.000694	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—ESR1—osteoporosis	5.82e-05	0.000693	CbGpPWpGaD
Bosentan—CYP2C9—Biological oxidations—POMC—osteoporosis	5.64e-05	0.000671	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—IRS1—osteoporosis	5.44e-05	0.000647	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—FDPS—osteoporosis	5.32e-05	0.000633	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—PKM—osteoporosis	5.32e-05	0.000633	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—POMC—osteoporosis	5.23e-05	0.000623	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—IL6R—osteoporosis	5.11e-05	0.000608	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—ADCY5—osteoporosis	5.09e-05	0.000607	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—GPD2—osteoporosis	5.04e-05	0.0006	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—PGLS—osteoporosis	5.04e-05	0.0006	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—IGF1—osteoporosis	5.03e-05	0.0006	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—SPP1—osteoporosis	4.93e-05	0.000587	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—CYP19A1—osteoporosis	4.8e-05	0.000572	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—ATIC—osteoporosis	4.61e-05	0.000549	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—PNP—osteoporosis	4.61e-05	0.000549	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—IRS2—osteoporosis	4.46e-05	0.000531	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—LEP—osteoporosis	4.36e-05	0.000519	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—ESR1—osteoporosis	4.16e-05	0.000496	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—ADCY5—osteoporosis	3.92e-05	0.000467	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—OXCT1—osteoporosis	3.92e-05	0.000467	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—CA2—osteoporosis	3.92e-05	0.000467	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—GPX1—osteoporosis	3.91e-05	0.000466	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—IRS1—osteoporosis	3.89e-05	0.000463	CbGpPWpGaD
Bosentan—EDNRB—Signaling by GPCR—IL6—osteoporosis	3.85e-05	0.000459	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—MGLL—osteoporosis	3.82e-05	0.000455	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—POMC—osteoporosis	3.75e-05	0.000446	CbGpPWpGaD
Bosentan—CYP3A4—Biological oxidations—POMC—osteoporosis	3.72e-05	0.000443	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—IL6R—osteoporosis	3.65e-05	0.000435	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—MTHFR—osteoporosis	3.61e-05	0.00043	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—IGF1—osteoporosis	3.6e-05	0.000429	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism of lipids and lipoproteins—CYP19A1—osteoporosis	3.6e-05	0.000429	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—PKM—osteoporosis	3.51e-05	0.000418	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—FDPS—osteoporosis	3.51e-05	0.000418	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—PGLS—osteoporosis	3.32e-05	0.000396	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—GPD2—osteoporosis	3.32e-05	0.000396	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—IDH2—osteoporosis	3.25e-05	0.000387	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—CYP27A1—osteoporosis	3.05e-05	0.000364	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—ATIC—osteoporosis	3.04e-05	0.000362	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—PNP—osteoporosis	3.04e-05	0.000362	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—MYC—osteoporosis	3.03e-05	0.00036	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—TGFB1—osteoporosis	3.02e-05	0.00036	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—ACP5—osteoporosis	2.97e-05	0.000354	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—osteoporosis	2.93e-05	0.000349	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—POMC—osteoporosis	2.89e-05	0.000344	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—TPI1—osteoporosis	2.76e-05	0.000329	CbGpPWpGaD
Bosentan—EDNRA—Signaling by GPCR—IL6—osteoporosis	2.76e-05	0.000328	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—P4HB—osteoporosis	2.6e-05	0.000309	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—CA2—osteoporosis	2.58e-05	0.000308	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—OXCT1—osteoporosis	2.58e-05	0.000308	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—GAPDH—osteoporosis	2.55e-05	0.000303	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—MGLL—osteoporosis	2.52e-05	0.0003	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—RAP1A—osteoporosis	2.48e-05	0.000296	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—IL6—osteoporosis	2.27e-05	0.000271	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—MYC—osteoporosis	2.17e-05	0.000258	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism of lipids and lipoproteins—POMC—osteoporosis	2.16e-05	0.000258	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—TGFB1—osteoporosis	2.16e-05	0.000257	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—IDH2—osteoporosis	2.14e-05	0.000255	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—CYP27A1—osteoporosis	2.01e-05	0.00024	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—ENO1—osteoporosis	2.01e-05	0.000239	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—PSMA5—osteoporosis	1.98e-05	0.000235	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—PSMA2—osteoporosis	1.98e-05	0.000235	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—ACP5—osteoporosis	1.96e-05	0.000233	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—TPI1—osteoporosis	1.82e-05	0.000217	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—P4HB—osteoporosis	1.71e-05	0.000204	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—GAPDH—osteoporosis	1.68e-05	0.0002	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—RAP1A—osteoporosis	1.64e-05	0.000195	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—IL6—osteoporosis	1.63e-05	0.000194	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—CYP19A1—osteoporosis	1.6e-05	0.000191	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—ENO1—osteoporosis	1.32e-05	0.000158	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—ADCY5—osteoporosis	1.31e-05	0.000156	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—GPX1—osteoporosis	1.31e-05	0.000156	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—PSMA2—osteoporosis	1.3e-05	0.000155	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—PSMA5—osteoporosis	1.3e-05	0.000155	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—MTHFR—osteoporosis	1.21e-05	0.000144	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—CYP19A1—osteoporosis	1.06e-05	0.000126	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—POMC—osteoporosis	9.64e-06	0.000115	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—ADCY5—osteoporosis	8.64e-06	0.000103	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—GPX1—osteoporosis	8.61e-06	0.000103	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—MTHFR—osteoporosis	7.95e-06	9.47e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—POMC—osteoporosis	6.36e-06	7.57e-05	CbGpPWpGaD
